TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17289855
Drug: Unilateral eccentric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unilateral eccentric body load training using a decline board twice a week
Study: 15336780
Drug: Post-vaccine PBL
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-vaccine PBL
Study: 11148437
Drug: Lansoprazole-based triple
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole-based triple therapy for 7 days
Study: 8929937
Drug: Willingness for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness for treatment
Study: 8929937
Drug: Treatment tenure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment tenure
Study: 2780404
Drug: No exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercise treatment (Control Group)
Study: 329423
Drug: Delta-9-tetrahydrocannabinol (0.022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta-9-tetrahydrocannabinol (0.022 mg/kg and 0.044 mg/kg)
Study: 31818699
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual film (10-35 mg)
Study: 31818699
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual film
Study: 26472122
Drug: Low-dose X-ray
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose X-ray system with advanced real-time image processing
Study: 16507327
Drug: Aprinocarsen (2mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprinocarsen (2mg/kg/day continuous iv infusion for the first 14 days of each cycle), combined with gemcitabine (1,250 mg/m² on days 1 and 8) and carboplatin (AUC 5 on day 1 every 21 days).
Study: 14747106
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (suturing)
Study: 9164203
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of standard adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy
Study: 9164203
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of perioperative CMF therapy
Study: 8394880
Drug: ImuVert and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ImuVert and radiation therapy (RT)
Study: 29864779
Drug: Vorapaxar (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar (10 mg initial dose, potentially an additional 10 mg based on aggregometry)
Study: 22049096
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily for six months
Study: 22049096
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice daily for six months
Study: 16551284
Drug: Hemodialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis dose defined by K/DOQI guidelines (spKt/V of 1.2)
Study: 16551284
Drug: Hemodialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis dose defined by European guidelines (spKt/V of 1.4)
Study: 16551284
Drug: Normalization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normalization of dialysis dose for low molecular weight water-soluble solutes (urea)
Study: 16551284
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of spKt/V or eKt/V for routine monitoring of hemodialysis dose
Study: 16551284
Drug: Dialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis dose dependent on gender
Study: 16551284
Drug: Dialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis dose for middle molecules in clinical practice
Study: 16551284
Drug: Dialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis dose for more frequent hemodialysis treatment strategies
Study: 15451901
Drug: Insulin glulisine/NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glulisine/NPH (n = 435)
Study: 15451901
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RHI)/NPH (n = 441)
Study: 10633218
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose infusion of insulin (HDT)
Study: 10633218
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose infusion of insulin (LDT)
Study: 8659772
Drug: Sustained-release ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release ibuprofen, 2 x 800 mg (n = 57)
Study: 2058222
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (400 mg)
Study: 2058222
Drug: Theophylline administered
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline administered via endoscope into the colon transversum
Study: 6097457
Drug: ACTH 4-9
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-9 analogue (40 mg)
Study: 31246579
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (2000-2500 g)
Study: 31246579
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (2500-3000 g)
Study: 31246579
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (3000-3500 g)
Study: 31246579
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (3500-4000 g)
Study: 28810909
Drug: Eosinophil-guided corticosteroid-sparing
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil-guided corticosteroid-sparing therapy (prednisolone not administered if eosinophil level < 0.3 × 10^9 cells/L)
Study: 28810909
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (5-day course of high-dose systemic corticosteroids)
Study: 28810909
Drug: Eosinophil-guided corticosteroid-sparing
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil-guided corticosteroid-sparing therapy
Study: 22821925
Drug: US-guided pararadicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided pararadicular injections
Study: 21082298
Drug: Oral caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral caffeine 200 mg
Study: 21082298
Drug: Oral caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral caffeine 400 mg
Study: 19118324
Drug: Haloperidol (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-15 mg/day)
Study: 11242608
Drug: Inhaled flunisolide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled flunisolide, 500 mg twice a day for 2 years
Study: 11242608
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (asthma patients not requiring glucocorticoid treatment)
Study: 8452386
Drug: l-leucovorin 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-leucovorin 250 mg/m2 weekly
Study: 8452386
Drug: l-leucovorin 100
Normalized name: leucovorin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-leucovorin 100 mg/m2 for 5 consecutive days
Study: 8452386
Drug: l-leucovorin 10
Normalized name: leucovorin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-leucovorin 10 mg/m2 for 5 consecutive days
Study: 3512663
Drug: Slo-bid capsules
Normalized name: Slo-bid
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slo-bid capsules
Study: 24648266
Drug: ALL-related treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALL-related treatments
Study: 20979455
Drug: Intranasal Norwalk
Normalized name: Norwalk virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Norwalk VLP vaccine (100-μg dosage)
Study: 20979455
Drug: Intranasal Norwalk
Normalized name: Norwalk virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Norwalk VLP vaccine (50-μg dosage)
Study: 20979455
Drug: Intranasal Norwalk
Normalized name: Norwalk virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Norwalk VLP vaccine (50-μg and 100-μg dosages)
Study: 11951579
Drug: 5% ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ibuprofen cream (Dolgit cream), applied in a 10-cm strip t.i.d. for 7 days, each strip containing approximately 200 mg ibuprofen.
Study: 11951579
Drug: Placebo cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, applied in the same manner as the ibuprofen cream.
Study: 8090332
Drug: Oral 1
Normalized name: SYRINGE,ORAL 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Study: 8090332
Drug: Intravenous 1
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Study: 8090332
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Study: 8090332
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intraperitoneal 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Study: 8090332
Drug: Oral, intraperitoneal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Study: 30912719
Drug: CT examinations
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT examinations with intravenous contrast agent (n = 4263)
Study: 30912719
Drug: CT examinations
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT examinations without intravenous contrast agent (n = 16,111)
Study: 25933487
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 900 mg of eicosapentaenoic acid plus 680 mg of docosahexaenoic acid for 4 weeks
Study: 19748293
Drug: IANB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB plus buccal infiltration (BI)
Study: 19748293
Drug: IANB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB plus periodontal ligament (PDL) injection
Study: 10763910
Drug: Phentermine hydrochloride
Normalized name: Phentermine Hydrochloride
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine hydrochloride therapy plus a low energy diet (5040 kJ/d)
Study: 8973780
Drug: Lacidipine-based treatment
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine-based treatment
Study: 8973780
Drug: Beta-blocker (atenolol)-based
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (atenolol)-based treatment
Study: 1611652
Drug: Cefprozil (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (administered once daily for ten days)
Study: 1611652
Drug: Cefaclor (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (administered three times a day for ten days)
Study: 6142351
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of metaraminol infusion
Study: 6142351
Drug: Prophylactic colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic colchicine therapy
Study: 25767259
Drug: GSK‐1614235 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK‐1614235 (20 mg) premeal dosing
Study: 20690094
Drug: Early and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early and intensive statin therapy (60 mg immediately and 40 mg/day atorvastatin)
Study: 20690094
Drug: Conventional statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional statin therapy (10 mg/day atorvastatin)
Study: 19178799
Drug: Amoxicillin/clavulante for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulante for 3 weeks after FESS
Study: 19178799
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic after FESS (Control group)
Study: 16618013
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg DHEC (Almirid 40 mg test T)
Study: 16618013
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 20 mg DHEC (Almirid 20 mg reference R)
Study: 10576464
Drug: Paroxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10 to 40 mg daily)
Study: 10576464
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 to 40 mg daily)
Study: 6359887
Drug: Metoprolol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (a beta 1‐adrenergic antagonist)
Study: 6359887
Drug: High-dose terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose terbutaline
Study: 6359887
Drug: Infusion dosages
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion dosages above 40 micrograms/min
Study: 25006120
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine + volasertib (LDAC + volasertib)
Study: 18072875
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of calcium citrate daily (500 mg with meals)
Study: 18072875
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of calcium citrate daily
Study: 12970287
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/d (RLX60)
Study: 12970287
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg/d (RLX120)
Study: 10792117
Drug: Rifaximin, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin, 1200 mg/day (400 mg t.d.s.)
Study: 10792117
Drug: Chlortetracycline, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortetracycline, 1 g/day (333 mg t.d.s.)
Study: 9240777
Drug: Intraoperative mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative mitomycin-C (0.04%) as a single dose
Study: 1467256
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of social relations programme and cooperative learning
Study: 30774069
Drug: DRIFT (drainage,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRIFT (drainage, irrigation and fibrinolytic therapy)
Study: 30774069
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (cerebrospinal fluid tapping)
Study: 19260949
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of simvastatin and bezafibrate
Study: 16525137
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg once daily for 52 weeks
Study: 10434907
Drug: Quantitative analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative analysis of enhancement patterns using T1 weighted spoiled gradient recalled echo (SPGR) images during bolus intravenous injection of 0.1 mmol kg‐1 of Gd‐chelate
Study: 22186072
Drug: Pyrimethamine-sulphonamide treatment
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine-sulphonamide treatment for 3 months followed by Fansidar(®) for 9 months
Study: 11049014
Drug: Prescribed drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed drugs
Study: 11049014
Drug: Over-the-counter (OTC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter (OTC) drugs
Study: 11049014
Drug: Central nervous
Normalized name: CENTRAL NERVOUS SYSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central nervous system (CNS) drugs
Study: 11049014
Drug: OTC drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC drugs
Study: 11049014
Drug: Potential drug
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential drug interactions
Study: 9052345
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 or 20 mg) and Felodipine ER (2.5, 5, or 10 mg)
Study: 9052345
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg) and Felodipine ER (10 mg)
Study: 9052345
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg) and Felodipine ER (2.5 mg)
Study: 3329515
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg benzhexol
Study: 27070250
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) treatment for 2 weeks, 14-minute sessions
Study: 27070250
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) treatment
Study: 25023033
Drug: Sequential rescue
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential rescue therapies
Study: 18710676
Drug: Self-reported daily
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported daily smoking
Study: 18710676
Drug: Cotinine concentration
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotinine concentration cutoff of 10 ng/mL
Study: 18710676
Drug: Cotinine concentration
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotinine concentration cutoff of 30 ng/mL
Study: 12891299
Drug: simvastatin (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (10‐20 mg/day), clopidogrel (75 mg/day), and trimetazidine (60 mg/day) for 6 months
Study: 11146601
Drug: Anti epileptic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti epileptic medication
Study: 8858649
Drug: Nebulizer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer treatment group
Study: 8858649
Drug: MDI-spacer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-spacer treatment group 1
Study: 8858649
Drug: MDI-spacer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-spacer treatment group 2
Study: 3300424
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine (4, 6, and 8 mg in saline; 6 mg in 10% glucose)
Study: 8773867
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3 mg)
Study: 28962912
Drug: Lumbar transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar transforaminal epidural steroid injections (TFESIs)
Study: 23997095
Drug: PEMI after
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEMI after sublingual administration of 5 mg of isosorbide dinitrate (ISDN)
Study: 16583466
Drug: Single SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC doses of 0.5, 1.5, or 3.0 mg/kg
Study: 16583466
Drug: SC doses
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC doses of 100 mg every 2 weeks (3 injections)
Study: 16583466
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg IV infliximab every 2 weeks (2 infusions) followed by 100 mg SC every 2 weeks (3 injections)
Study: 16583466
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg IM every 2 weeks (3 injections)
Study: 16583466
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SC every 4 weeks (3 injections)
Study: 30945515
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (N=40)
Study: 28760205
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy with edoxaban
Study: 28760205
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or no antithrombotic therapy (control group)
Study: 23381494
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone furoate (MF)
Study: 19351223
Drug: Aceclofenac-paracetamol combination
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac-paracetamol combination (100 mg aceclofenac + 500 mg paracetamol bid)
Study: 19351223
Drug: Aceclofenac alone
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac alone (100 mg bid)
Study: 19351223
Drug: Aceclofenac-paracetamol combination
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac-paracetamol combination
Study: 17032347
Drug: Product of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product of insulin sensitivity and insulin secretion (B-beta)
Study: 11444253
Drug: docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 100 mg/m2
Study: 11444253
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2
Study: 11444253
Drug: vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 30 mg/m2 or ifosfamide 2 g/m2
Study: 8053664
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human nerve growth factor (rhNGF) intravenous or subcutaneous doses ranging from 0.03 to 1 micrograms/kg
Study: 8053664
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human nerve growth factor (rhNGF) at doses above 0.1 microgram/kg